Monoclonal antibodies such as anifrolumab (a monoclonal antibody antagonist of the type 1 interferon receptor (IFNAR) developed for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis [95] or sifalimumab (immunoglobulin G1-κ monoclonal antibody that binds and neutralizes most IFN-α subtypes)) [96] may be effective in these patients. The gene discussed is IFNAR1; the disease is systemic lupus erythematosus.